Principal Scientist, Antibody Engineering
Apr 2020 – Present- Set the developability strategy for an 8-program antibody portfolio and lead 11 scientists across two sites
- Advanced 3 bispecific antibodies into Phase 1 on schedule, each clearing FDA review without CMC holds
- Introduced an in silico developability screen that cut late-stage aggregation failures by 60%